Conventional-dose bicalutamide (50mg/d) as the second-line hormonal therapy for androgen independent

来源 :4th Forum of Prostate Disease (第四届全国前列腺疾病综合诊治新进展学术研讨会) | 被引量 : 0次 | 上传用户：VIPT250

【作者】

：

Zhengwang Zhang Weiqing Qian Jianda Song Lu Sheng Huixing Wu Dongya Wang Haojie Zhang Haiyong Ding Zhongquan Sun

【机构】

：

Huadong Hospital affiliated to Fudan University

【出处】

：

4th Forum of Prostate Disease (第四届全国前列腺疾病综合诊治新进展学术研讨会)

【发表日期】

：

2009年12期

【关键词】

：

antineoplastic agents China hormonal prostatic neoplasm

下载到本地 , 更方便阅读

下载此文赞助VIP

声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架

论文部分内容阅读

其他文献

Semiparametric regression for cis-regulatory organization of the genes in prostate cancer pathway on

会议

semiparametric regressioncis-regulatoryprostate cancerkernel machines

Extraperitoneal laparoscopic radical prostatectomy:An experience of single surgeon

会议

laparoscopyprostatectomyextraperitoneal

The comparison on the clinic effect of TUVP, TUEVAP and TURP for BPH

会议

Benign prostatic hyperplasiaTUVPTUEVAPTURPclinic effect

Association of TMPRSS2 and KLK11 gene expression levels with clinical progression of human prostate

会议

Prostate cancerTMPRSS2KLK11Clinical pathologyPrognosis

Nuclear expression of Survivin is an independent predictor for progression of prostate adenocarcinom

会议

Prostate adenocarcinomaSurvivinNuclear

The value of prostate-specific antigen doubling time for patients with prostate cancer after maximal

会议

prostatic neoplasmsprostate-specific antigenprostate-specific antigen doubling

How to deal with bladder outlet obstruction (BOO) and lower urinary tract symptoms (LUTS) caused by

会议

prostatic hyperplasiaTURPTUIBN

The learning curve of holmium laser enucleation of the prostate

会议

learning curveBPHsurgery

Development and internal validation of a nomogram predicting the probability of pT3 at radical prost

会议

prostate cancernomogramradical prostatectomy

In vitro anti-tumor immune response induced by dendritic cells transduced with truncated PSMA and 4-

会议

dendritic cellsPSMA

Conventional-dose bicalutamide (50mg/d) as the second-line hormonal therapy for androgen independent

与本文相关的学术论文